NG
GILD icon

Novem Group’s Gilead Sciences GILD Stock Holding History

Novem Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Sell
2,256
-168
-7% -$22.1K 0.03% 367
2026
Q1 		$338K Buy
2,424
+200
+9% +$28K 0.04% 331
2025
Q4 		$273K Buy
2,224
+85
+4% +$10.3K 0.03% 352
2025
Q3 		$237K Sell
2,139
-711
-25% -$80.8K 0.03% 368
2025
Q2 		$316K Sell
2,850
-796
-22% -$84.7K 0.04% 312
2025
Q1 		$409K Buy
+3,646
New +$376K 0.06% 248

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Novem Group's GILD Position: Q2 2026 in Review

Novem Group reduced its Gilead Sciences (GILD) stake by 6.9% in Q2 2026, selling an estimated $22.1K and leaving 2,256 shares worth $285K. The position accounts for 0.03% of the portfolio, ranked #367.

Novem Group first reported a position in GILD in Q1 2025 and has held it in 6 quarters since. The position peaked at $409K in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Novem Group held 2,256 shares of Gilead Sciences worth $285K as of Q2 2026.
  • Novem Group sold 168 Gilead Sciences shares in Q2 2026, an estimated $22.1K.
  • Gilead Sciences made up 0.03% of Novem Group's portfolio in Q2 2026, its #367 holding.
  • Novem Group first reported a position in Gilead Sciences in Q1 2025 and has held it in 6 quarters since.
  • Novem Group's Gilead Sciences position peaked at $409K in Q1 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Novem Group's 13F filing for Q2 2026, filed 21 Jul 2026.